TICARCILLIN-CLAVULANIC ACID PHARMACOKINETICS IN PRETERM NEONATES WITH PRESUMED SEPSIS

被引:12
作者
BURSTEIN, AH
WYBLE, LE
GAL, P
DIAZ, PR
RANSOM, JL
CARLOS, RQ
FORREST, A
机构
[1] UNIV S FLORIDA,COLL MED,DEPT PEDIAT,TAMPA,FL 33606
[2] MOSES CONE MEM HOSP,GREENSBORO AREA HLTH EDUC CTR,GREENSBORO,NC
[3] WOMENS HOSP GREENSBORO,GREENSBORO,NC
[4] SUNY BUFFALO,SCH PHARM,CTR CLIN PHARM RES,BUFFALO,NY 14260
关键词
D O I
10.1128/AAC.38.9.2024
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The objective of the reported study was to characterize the pharmacokinetics of ticarcillin and clavulanic acid in premature low-birth-weight (less than 2,200 g) neonates with presumed sepsis. Eleven infants received 12 courses of ticarcillin-clavulanic acid at 75 mg/kg of body weight intravenously every 12 h. Blood samples were collected at 0.5, 1.5, 4, and 8 h following the infusion of the initial dose. The concentrations of ticarcillin and clavulanic acid were determined by a microbiologic assay. Median (interpatient coefficients of variation) values for the volume of the central compartment, total steady-state volume, distributional clearance, total clearance, and terminal elimination half-life for ticarcillin were 0.030 liter/kg (21%), 0.26 liter/kg (48%), 0.41 liter/h/kg (47%), 0.047 liter/h/kg (47%), and 4.2 h (45%), respectively. For clavulanic acid the parameters were 0.28 liter/kg (32%), 0.36 liter/kg (34%), 11 liters/h/kg (36%), 0.12 liters/h/kg (72%), and 1.95 h (40%), respectively. Our results suggest that the current dosing recommendations of 75 mg/kg every 12 h risk subtherapeutic clavulanic acid concentrations and that 50 mg/kg every 6 h is a more rational dosing strategy.
引用
收藏
页码:2024 / 2028
页数:5
相关论文
共 15 条
[1]  
Akaike H., 1976, MATH SCI, V14, P5
[2]   PHARMACOKINETICS AND DRUG DISTRIBUTION DURING POSTNATAL-DEVELOPMENT [J].
ASSAEL, BM .
PHARMACOLOGY & THERAPEUTICS, 1982, 18 (02) :159-197
[3]   SIMPLIFIED SCORE FOR ASSESSMENT OF FETAL MATURATION OF NEWLY BORN INFANTS [J].
BALLARD, JL ;
NOVAK, KK ;
DRIVER, M .
JOURNAL OF PEDIATRICS, 1979, 95 (05) :769-774
[4]   KINETIC INTERACTIONS OF TAZOBACTAM WITH BETA-LACTAMASES FROM ALL MAJOR STRUCTURAL CLASSES [J].
BUSH, K ;
MACALINTAL, C ;
RASMUSSEN, BA ;
LEE, VJ ;
YANG, YJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :851-858
[5]  
DARGENIO D, 1992, ADAPT 2 USERS GUIDE
[6]   OPTIMAL SAMPLING TIMES FOR PHARMACOKINETIC EXPERIMENTS [J].
DARGENIO, DZ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1981, 9 (06) :739-756
[7]  
DAVIES BE, 1985, INT J CLIN PHARM TH, V23, P70
[8]   AN EVALUATION OF OPTIMAL SAMPLING STRATEGY AND ADAPTIVE STUDY DESIGN [J].
DRUSANO, GL ;
FORREST, A ;
SNYDER, MJ ;
REED, MD ;
BLUMER, JL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (02) :232-238
[9]   THE PROPHYLACTIC USE OF TICARCILLIN CLAVULANATE IN THE NEONATE [J].
FAYED, SB ;
SUTTON, AM ;
TURNER, TL ;
MCALLISTER, TA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 19 (01) :113-118
[10]   KINETIC STUDIES ON INACTIVATION OF ESCHERICHIA-COLI RTEM BETA-LACTAMASE BY CLAVULANIC ACID [J].
FISHER, J ;
CHARNAS, RL ;
KNOWLES, JR .
BIOCHEMISTRY, 1978, 17 (11) :2180-2184